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ABSTRACT
DIFFERENTIAL ENDOMETRIAL RESPONSES OF
PRIMATES VS RODENTS: SCREENING FOR
ANTIPROLIFERATIVE EFFECTS OF ANTIPROGESTINS
David Williams Burleigh
Eastern Virginia Medical School
and
Old Dominion University, 1997
Director D r Gary D. Hodgen
The antiprogestin, mifepristone, has previously been shown to noncompetitively
inhibit estrogen-induced endometrial proliferation in nonhuman primates (van Uem et al.,
1989; Wolf et al., 1989b; Neulen et al., 1990; Neulen et al., 1996). For both economical
and ethical reasons, we are encouraged to identify comparative laboratory rodent models
which can substitute the need to use primate models. In the following study, we compared
capabilities of the rat uterine weight bioassay versus a primate uterine bioassay, to identify
the noncompetitive antiestrogenic/antiproliferative effects of mifepristone.
Long-term ovariectomized monkeys were exposed to exogenous l7|3-estradiol
(E2) and mifepristone in doses and regimes already demonstrated to curtail endometrial
growth (Wolf et al., 1989b). Results show that mifepristone decreased endometrial
proliferation in a dose-dependent manner, and this decrease occurred in the presence of
physiologic serum E2 levels.
In the rat model, ovariectomized immature (day 20) and adult Sprague-Dawley
rats were pretreated with E2 for 3 days, followed by E2 plus mifepristone (various doses)
for 3 additional days. E2 replacement was either given as 0.5 pg/100 g body weight (in oil,
sc) or as a 0.5 mg sc pellet. Mifepristone did not induce a decrease in uterine wet or
blotted weights in immature or adult rats receiving E2 replacement as 0.5 pg/100 g body
weight (P>0.05). This lack of effect was not due to insufficient E2 stimulation as
histological evaluation of the endometrium showed increased numbers of mitotic figures in
all treatment groups and serum E2 levels were in the diestrous-proestrous range. In
contrast, mifepristone did inhibit an increase in uterine wet weight of adult rats (P<0.05)
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and immature rats (P<0.01) receiving E2 replacement as O.S mg E2 pellet. Uterine blotted
weights were also effected by treatment with mifepristone in the immature rats (P<0.05).
Serum E2 levels attained in rats given the O.S mg E2 pellet were pharmacological (>800
pg/ml), illustrating a relationship between E2 levels and capability o f mifepristone to affect
rat uterine weight.
Based on the results summarized here, we do not recommend using the rat uterine
weight bioassay as a substitute model for screening antiprogestins for noncompetitive
antiestrogenic/antiproliferative effects on primate uterine endometrium.
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I

INTRODUCTION

History

The drug RU38486 (17p-hydroxy-l 1p-(4-dimethyIaminophenyl)-17a-( 1propynyl)-estra-4, 9-dien-3-one; Roussel-Uclaf), also called mifepristone, was developed
in 1980 as a potential antiglucocorticoid. Because previous company data showed some
binding cross-reactivity between the glucocorticoid receptor (GR) and the progesterone
receptor (PR), Roussel-Uclaf conducted receptor binding tests to identify possible
receptor cross-reactivity. The receptor binding tests revealed that mifepristone, in addition
to recognizing the glucocorticoid receptor, showed significant binding affinity for the
progesterone receptor; and to a much lesser extent, the androgen receptor (Baulieu,
1989). This cross-reactivity is not surprising as subsequent work has shown a 90% amino
acid sequence identity in the GR and PR DNA-binding regions and a 55% amino acid
sequence identity in the COOH-terminal region (Evans, 1988).
As the capability of a synthetic steroid compound to bind a steroid receptor can
not accurately predict its in vivo agonistic or antagonistic effects (Baulieu, 1989), studies
evaluating the antiprogestational effects of RU486 were necessary. The secretion of
progesterone by the corpus luteum is well known to be necessary for the maintenance of
pregnancy in women (Csapo et al., 1972; Jones, 1976), as luteectomy followed by
progesterone replacement therapy prevents pregnancy loss (Csapo et al., 1973). Philibert
and others (1982) evaluated the use of mifepristone to block progesterone action and
induce termination of pregnancy in rats. Building from the success of these experiments,
the capability of mifepristone to block progesterone action and induce abortion in women
was also investigated. Principally due to mifepristone’s capability to induce early
pregnancy termination in women, the steroid quickly became labeled by anti-abortion
groups as the abortion-pill.
The following dissertation text style is modeled after Molecular Reproduction and
Development.
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Multiple uses for mifepristone have been proposed and identified, including, ovulation
inhibition (Danforth et al., 1989; Wolfet al., 1989a), treatment for breast cancer
(McDonnell and Goldman, 1994), pregnancy termination (Ulmann, 1987; Ji, 1988),
contragestation (Glasier et aL, 1992; Webb et al., 1992),
treatment of leiomyomas (Murphy et al., 1993), treatment of progesterone receptor
containing meningiomas (Grunberg, 1994), and treatment of endometriosis (Kettel et al,
1991; Grow et al., 1996; Kettel et al., 1996). Yet, it is the highly controversial abortive
properties of the drug that have garnered so much attention of the press and public and
made RU486 recognized.
Generalized Description of Gene Transcription

Figure 1A diagrams a very simplified representation of a steroid-inducible
eukaryotic gene. In general, the transcription of mRNA from such a gene requires RNA
polymerase II and accessory proteins which recognize the promoter sequence. These
accessory proteins are termed transcription factors, which are proteins needed for the
initiation of transcription but are not themselves a component of RNA polymerase Q. The
promoter is a region of DNA that contains binding sites for the transcription factors. Most
eukaryotic promoters contain the consensus sequence TATA approximately 25 base pairs
upstream of the transcription start site. In addition, the gene sequence contains a hormone
response element (HRE). The HRE is a DNA binding site that induces transcription when
activated by its respective Iigand-receptor complex, and prevents transcription in the
nonactivated state; thereby regulating hormone-induced transcription. Steroid receptors
are proteins that can be viewed as ligand-dependent transcription factors (Kraus et al.,
1995). It is generally accepted that unliganded steroid receptors reside within the nucleus
and are believed to be loosely associated with DNA (Mester and Baulieu, 1995; Catt,
1996). Following activation by a ligand, the receptors undergo tight DNA binding to the
hormone response element (HRE) and initiate gene activation.
Figure IB illustrates a possible model for activation of an estrogen-inducible gene.
Upon entering the cell, estrogen binds to its receptor (ER) and promotes tight association
of the Iigand-receptor complex to the estrogen response element (ERE). Binding of the
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activated estrogen-receptor complex to the ERE initiates formation of the transcription
complex and the binding of RNA polymerase II. It is thought that binding of the estrogenreceptor complex to the ERE likely induces a change in the three dimensional structure of
the gene, bringing the transcription complex into close physical contact with the estrogenreceptor complex (Nardulli et al., 1993). Interaction between these two elements activates
RNA polymerase II and initiates mRNA transcription. Translation of the mRNA leads to
the synthesis of proteins with various functions, among them, regulation of cell growth
and mitogenesis.

A.
HRE
5’

|— Promoter region —}
TATA Start site

Stop site
3’

H —
-100 bp

-25 bp 0

B.
E2-ER

3’

Promoter-Transcription complex

Fig. I. Conceptualized view of steroid-inducible gene activation. (A) Illustrates binding regions for the
promoter complex and hormone receptor complex. (B) Binding of the activated estrogen receptor complex
to the ERE induces a 3-D change in the gene and brings the promoter complex into close physical contact
with the receptor, initiating mRNA transcription. Model adapted from Kraus and others (1995).
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Cell Cycle

The progression of a cell through the cell cycle, is in part, regulated by the activity
of a special class of protein kinases called cyclin-dependent kinases. In turn, activation of
the cyclin-dependent kinases are positively regulated by association with a catalytic
subunit called cyclin. Numerous cyclins have been identified and classified according to
their conserved amino acid sequence motifs, and apparent function (Geum et al., 1997).
Cyclin-dependent kinase Dl has been identified in steroid regulation of cell growth and
appears to be necessary for progesterone-dependent mammary development, as cyclin Dldeficient mice do not develop lobular mammary alveoli during pregnancy (Musgrove et
ai., 1997). Cyclin-dependent inhibitor, p21, is known to inhibit cyclin-dependent kinase
activity. In the G( phase of the cell cycle (Figure 2), D-type cyclins are involved in
activating the powerful growth-inhibitory protein retinoblastoma tumor suppresser protein
(pRB). When pRB is hypophosphorylated it actively blocks cell mitosis by sequestering
transcription factors. Cyclin-dependent kinase Dl is involved in the hyperphosphoryiation
of pRB, which then releases the transcription factors and allows the progression of cell
mitotis (Weinberg, 1996).
Musgrove and others (1997) have recently presented data describing mifepristoneinduced cell cycle inhibition in T-47D breast cancer cells. T-47D cells are progesterone
responsive cancer cells and are frequently used by investigators to study the in vitro
effects of progestins. In these experiments a 3- to 4-fold increase in p21 levels was
observed in the cells 12-24h after treatment with mifepristone. The increase in p21 levels
was associated with a decrease in cyclin-D 1 kinase activity and an increase in the ratio of
hypophosphorylated pRB.hyperphosphorylated pRB.
These data would strongly indicate that mitotic arrest of T-47D cells (and possibly
other types of progesterone responsive cells) by mifepristone is due to an upregulation of
p21, decreased activity of cyclin-D 1 kinase, and inactivation of pRB. These actions most
likely occur during Gi phase, at which point in time proteins required for mitosis are
synthesized. This would suggest that the lack of necessary cell-division proteins acts to
direct cells into a long-term, or permanent, Go phase (Cameron et aL, 1996).
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cytokinesis

Cell prepares
to divide

start of cycle

protein synthesis

cell rests
DNA
replication

restriction point where cell
commits to mitosis

Fig. 2. Stages of the cell cycle. Mifepristone-induced inhibition of cell mitosis may occur during the Gi
phase by altering the synthesis and activity of cell-division proteins. Model adapted from Weinberg
( 1996).

Repression of Estrogen-Induced In Vitro Transcription by Mifepristone

Four models describing the repression of transcription have been proposed by
Levine and Manley (1989) and Kraus and others (1995), these being, direct repression,
competitive repression, squelching, and quenching. In direct repression a repressor protein
binds to the DNA at a site distant to the promoter region and sterically interferes with
formation of the transcription complex. Competitive repression occurs when the repressor
protein binds to a DNA site overlapping or shared by the transcription complex, and
prevents its ability to bind to the DNA. In comparison, squelching is observed when the
over expression of a transcription factor sequesters other needed factors and prevents
them from forming the transcription complex. Lastly, quenching occurs when a repressor
and activator bind distinct DNA sites, yet interaction between the two prevents the
activator from making proper contact with the transcription complex.
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McDonnell and Goldman (1994) have proposed that mifepristone induces
antiestrogenic activities through the progesterone receptor A isoform; and not B isoform.
In their studies, monkey kidney CV-I fibroblasts were transiently transfected with a mouse
mammary tumor virus-estrogen response element-luciferase reporter. The transfected cells
also included expression vectors for human progesterone receptor A or B (PRA and
PRB), and an expression vector for hER. Results showed that luciferase activity was
decreased to approximately 60% of control levels in cells transfected with the PRA. This
decrease in luciferase activity was completely absent in cells transfected with the PRB;
indicating a partial estrogen receptor antagonism in cells coexpressing PRA. These authors
favored the mechanism of squelching to describe the noncompetitive inhibition of hER by
hPRA.
In a similar set of experiments by Kraus and others (1995), rat uterine cells were
transiently transfected with Rous sarcoma virus promoter-driven rat estrogen receptor
vector (pRSV-rER), pRSV-human progesterone receptor A (-hPRA), pRSV-hPRB,
hormone response elements ERE and PRE, and a chloramphenicol acetyltransferase
reporter gene. Results from these experiments showed that cells treated with mifepristone
had an approximately 85% decrease in CAT activity, regardless of which hPR isoform
they contained. These data would indicate that in rat uterine cells, both PRA or PRB can
act as an inhibitor of ER-mediated transcriptional activity. These authors supported the
model of quenching to explain their data on transcriptional repression of the ER by
activated PR.
Antiestrogenic Effects of Mifepristone in Primate Endometrium

Mifepristone was first reported to inhibit estrogen-induced endometrial
proliferation in the non-human primate by van (Jem and others (1989). van Uem and
others measured a decreased endometrial thickness in intact monkeys treated with
mifepristone. As mifepristone has been reported to not bind the ER (Moguilewsky and
Philibert, 1985), these authors concluded that the antiestrogenic effect of the antiprogestin
was very likely the result of noncompetitive actions. This experiment by van Uem and
others was quickly followed by an additional study from Wolf and others (1989b), who
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showed that mifepristone induced a decrease in endometrial thickness and reduced the
mitotic index in the endometrium of ovariectomized estrogen-supplemented monkeys. The
paradoxical noncompetitive antiestrogenic effect of mifepristone in nonhuman primates
has been supported by Slayden and Brenner (1994). These authors found that mifepristone
decreased uterine wet weight and increased amount of DNA per mg uterine tissue (DNA
M-g/mg tissue wet weight). Surprisingly, these antiestrogenic effects were only noted in the
endometrium and not the oviduct, thus showing tissue selectivity.
The mitogenic capacities of estrogen on uterine tissue are well known. As estrogen
induces transcription of cyclin-D 1 kinase mRNA during mouse uterine cell proliferation
(Geum et al., 1997), it is possible that cyclin-Dl, p21, or pRB proteins are effected during
the inhibition of estrogen-induced endometrial proliferation by mifepristone in nonhuman
primates. The atrophic appearance of mifepristone-treated nonhuman primate
endometrium is not due to decreased estrogen receptor concentration (Neulen et al., 1990;
Slayden and Brenner, 1994; Neulen et al., 1996).
Purpose

Since the late 1930s it has been established that the proestrus surge of estrogen in
rats stimulates uterine fluid retention (Astwood, 1939). Release of this uterine fluid is
accomplished by actions of progesterone in relaxing the cervix and allowing it to escape
via the vagina (Armstrong, 1968). Building upon this known effect of estrogen, the
standard accepted animal model assay used to assess the estrogenic or antiestrogenic
capability of new compounds is the m vivo immature rat uterine weight assay (Kirkland et
aL, 1979). In this assay, ovariectomized rats are given estradiol replacement to stimulate
water retention and endometrial proliferation. A positive estrogenic response can be
determined by an increase in uterine wet weight and uterine blotted weight, respectively.
The simultaneous administration of estradiol and an antiestrogenic compound should both
decrease water retention and uterine blotted weight, in comparison to the estradiol-treated
control. In regards to estrogen controlled growth, no model has been proven to be more
effective than the rat uterine bioassay. Accordingly, here we have compared the rodent
model with a primate model for evaluation of antiproliferative actions of mifepristone.
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Our laboratory has a continuing interest in examining the antiestrogenic effects of
mifepristone and other antiprogestins. The use of antiprogestins may be beneficial in
controlling breakthrough bleeding during progestin-only contraception (Williams et aL,
1997) and treatment of endometriosis (Grow et al., 1996; Kettel et al., 1996). While
evaluating the antiestrogenic effects of mifepristone using the rat uterine weight bioassay,
results from our preliminary experiments indicated that the bioassay might fail to identify
certain compounds capable of suppressing endometrial proliferation in nonhuman
primates, and as such, may not be suited for conventional high-throughput screening of
compounds. High throughput screening can be loosely defined as the testing of a large
number of compounds for detection of a limited number of specific endpoints. Based upon
whether these endpoints are observed, each compound is then accepted or eliminated from
further testing. Validity of this testing procedure is dependent on the chosen endpoints
truly reflecting the compounds’ desired capability. The negative results in our preliminary
studies are indirectly supported by two earlier studies. An acute study by Okulicz (1987)
indicated that ovariectomized rats retained E2-induced uterine fluid during treatment with
mifepristone. In addition, Szabo and others (1996) reported that proestrus rats given
mifepristone showed uterine imbibition [uterine ballooning]. Both of these studies
suggested that administration of mifepristone would not affect the estrogen-induced
accumulation in uterine fluid. As these two studies and our preliminary rat experiments
failed to show noncompetitive antiestrogenic/antiproliferative effects of mifepristone, we
chose to replicate the study of Kraus and Katzenellenbogen (1993) which reported
antiproliferative effects of mifepristone in immature rats. Replication of this study was
necessary to show that differences their and our study were due to experimental methods
(i.e., method of E2 replacement). In addition, we conducted an experiment using
cynomolgus monkeys to reassert that mifepristone does cause antiproliferative effects on
primate endometrium. Therefore, the goal of this study was to determine if a difference
exists between the rat uterine weight bioassay and a nonhuman primate uterine assay in
their capability to identify antiestrogenic effects of mifepristone. Those interested in the
screening of antiprogestin candidate compounds may benefit from our experiences and
observations reported herein.
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MATERIALS AND METHODS
Reagents

17P-estradiol and progesterone were purchased from Sigma Chemical Comp., (St.
Louis, MO). l7p-estradiol pellets were purchased from Innovative Research of America
(Cat. #E121, Sarasota, FL). The mifepristone used in these experiments was purchased
from China and its bioavailability and potency are equivalent to RU486.

Animals and Treatments

All Sprague Dawley rats used in these experiments were purchased from Harlan
Sprague Dawley, Inc. (Indianapolis, IN). The animals were maintained in a temperature
controlled room (24-27°C) under a 14h-10h, light-dark cycle, and given food and water
ad libitum. In the experiments using adult animals, females were ovariectomized when
approximately 250 g of weight and allowed a minimum of 10 days to recover before
starting hormone treatment. In experiments using immature animals, females were
ovariectomized on day 16 of age and allowed to recover for 4 days before starting
hormone treatment. The animals were randomly assigned to a treatment group following
ovariectomy (5 per group). Hormone treatments for animals of both ages were given for 6
days, 3 days of 17P-estradiol pretreatment (either l7f3-estradiol in oil or as a pellet),
followed by 3 days of 17P-estradiol plus mifepristone. 17p-estradiol was given as a daily
single sc injection (0.5 pg/100 g body weight (BW), in com oil) or as a single sc 0.5 mg
pellet implant. Mifepristone was dissolved in com oil and administered as a daily single sc
injection at the doses indicated in figures or tables. Vehicle control animals received the
appropriate volume of com oil. Cardiac blood samples were collected under ketaminerompun induced anesthesia from a group of similarly treated animals on days 1, 3, 5, and 7
for determination of estradiol levels.
Fifteen long-term ovariectomized cynomolgus monkeys (Macacafascicularis),
weighing approximately 2-4 kg, were maintained in a temperature controlled room (22°C)
with a I2h light-dark cycle, and given food and water ad libitum. The animals were

R ep ro d u ced with p erm ission o f the copyright ow ner. Further reproduction prohibited w ithout p erm ission.

10

assigned to one of five treatment groups (3 per group), as follows: 1, vehicle control, 3 cm
placebo containing silastic capsule, implanted sc, plus, daily sc injections of com oil; 2,
l7P-estradiol (E2) control, 3 cm estradiol containing silastic capsule (-150 mg E2),
implanted sc, plus, daily sc injection of com oil; 3, E2 capsule plus mifepristone (0.01
mg/kg/day, sc, in oil); 4, E2 capsule plus mifepristone (0.1 mg/kg/day, sc, in oil); 5, E2
capsule plus mifepristone (1.0 mg/kg/day, sc, in oil). The estradiol capsule was implanted
on day 1 and left in place for 21 days. Starting on day 1, animals were treated with vehicle
or mifepristone for 20 days. Femoral blood samples (3.5 cc) were collected under
ketamine-induced anesthesia on days 1, 5, 9, 13, 17, and 21 for determination of estradiol
levels.
Uterine Tissue Collection and Histology

One hour prior to tissue collection, all rats received a 0.1 ml sc injection of com oil
containing 5 |ig E2 and 2 mg progesterone to activate the steroid receptors and induce
nuclear translocation (Kraus and Katzenellenbogen, 1993). Rats were euthanized by C02
asphyxiation and the entire reproductive tract removed as one piece from the cervix to the
distal ends of the uterine homs. The tissue was stripped of fat and quickly weighed to
obtain the uterine wet weight, distal ends of the uterine homs were cut and the fluid gently
expelled, and the tissue was weighed again to obtain the uterine blotted weight. After
weighing, the uterine tissue was placed into 10% buffered formalin and processed for
hemotoxylin and eosin (H&E) staining.
Histology was performed on two cross-sections from each rat. Each cross-section
was morphologically examined for the number of mitotic figures in the endometrium and
glands. Mitotic activity was determined by counting the number of cells showing
metaphase chromosomes or a condensed nucleus with clear cytoplasm. Each cross-section
was also examined for the number of cells showing nuclear fragmentation.
Uterine biopsies were obtained from each monkey on day 21 of the experiment.
Full thickness endometrial biopsies were placed in 10% buffered formalin and processed
for H&E staining. Histological analysis of the endometrium was performed on a single
section by the criteria of Noyes and others (1950). Each section was morphologically
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examined for the number of mitotic figures in the endometrium, glands, and stroma.
Mitotic activity was determined by counting the number of cells showing metaphase
chromosomes or a condensed nucleus with clear cytoplasm. Mean endometrial thickness
for each animal was obtained by averaging at least four separate determinations using
Image-Pro Plus software (Media Cybernetics, Silver Spring, MD) on a Olympus BX50
microscope.
Radioimmunoassay

Monkey serum levels of 173-estradiol were measured by radioimmunoassay (RIA)
using a commercially available kit from ICN Biomedicals, Inc., (Costa Mesa, CA), and
quality control standards of known potency from BioRad (Hercules, CA). All serum
samples were measured in a single assay. The intraassay coefficient of variance for the
BioRad control of similar potency as the unknowns was 9%. Our labs historical interassay
coefficient of variance for this assay is <10%. The assay sensitivity for 173-estradiol was
10 pg/ml.
Rat serum levels of 173-estradiol were measured by Covance Laboratories Inc.,
(Vienna, VA), using an in-house assay with rabbit antiserum, HWA E2. Cross-reactivity
of this antiserum is 8.48% for 173-dihydroequilenin and negligible for all other tested
steroids. The reported intraassay coefficient of variance and interassay coefficient of
variance from Covance are 10.76% and 12% respectively. The assay sensitivity for 173estradiol was 10 pg/ml.
Preliminary Rat Experiments and Post-Ovariectomy Recovery Period

In our initial experiments (estrogen dose response curve and Preliminary
Experiments 1-4), adult Sprague Dawley rats, were purchased, cared for, and treated by
identical conditions as previously described; with the following exceptions. Both the
estrogen dose response experiment and Preliminary Experiment I used adult rats that had
a post ovariectomy recovery period of >4 days. The method of E2 replacement and/or
length of E2 treatment changed between experiments and is described with the associated
Figure and Tables.
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In the rat experiments presented herein, it is acknowledged that the post
ovariectomy recovery period, was a variable we did not totally control. Two experiments
with adult rats used a 4 day recovery period (approximately 1 estrous cycle). The recovery
period was increased to 10 days (2 estrous cycles) in all subsequent adult studies to
facilitate the clearance of all circulating ovarian steroids and to allow uterine atrophy prior
to experiment initiation. In the Latin Square design experiments that repeated a published
treatment regime (Kraus and Katzenellenbogen, 1993), we maintained our established 10
day surgery recovery period for adult rats, but observed the 4 day recovery period for
immature rats used by these authors.
For the following reasons, it is our beliefthat this variable did not play a role in
determining experimental outcome: 1) Immature rats were ovariectomized at 16 days of
age prior to the initiation of significant endogenous ovarian steroid production; 2) Serum
E2 levels were barely detectable in adult rats sampled 10 days after surgery; and 3)
Vehicle control tissue in all experiments consistently showed the lack of exposure to E2.
In addition, it is acknowledged that the length o f time from ovariectomy to
initiation of an experimental treatment is not consistent between monkeys and rats. Long
term ovariectomized monkeys (versus short-term) were used in these experiments for
reasons of availability, because steroid hormone levels were barely detectable, and because
maximal uterine atrophy had been established.
Statistical Analysis

Number of mitotic cells, cells showing nuclear fragmentation, uterine wet weight,
and uterine blotted weight, were statistically compared by analysis of variance using Instat
GraphPAD Software, version l.l la (1990). Significant differences between group means
were determined by Fisher’s least significant difference test, with values being considered
significant at P<0.05.
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Ethical Treatment of Animals

All animals were housed in facilities approved by the American Association for the
Accreditation of Laboratory Animal Care. These studies were approved by the Animal
Care and Use Committee of Eastern Virginia Medical School and carried out according to
NTH guidelines and USDA regulations.
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RESULTS
Monkey Endocrine Analysis

As expected, mifepristone was highly proficient in the inhibition of estrogen-driven
mitogenesis of primate endometrial tissue. These data confirm our prior published results
(van Uem et al., 1989; Wolf et aL, 1989b; Neulen et aL, 1990). All animals used in this
study were long-term ovariectomized (> 9 months). In order to stimulate growth of the
endometrium, monkeys received estrogen replacement therapy given as a 3 cm E2
containing silastic capsule, sc, for 21 days. The mean serum E2 levels attained in each
treatment group are shown in Figure 3. All treatment groups receiving an E2 capsule
maintained serum E2 levels in the physiological range. The higher serum E2 values in the
0.1 mg/kg mifepristone group were likely due to random variation in implant steroid
releasing kinetics.

Monkey estradiol levels

‘vehicle
'estradiol
-0.01 mg/kg
-aim gfkg
•LOwgftg

Fig. 3. Serum estradiol levels in monkeys given a 3 cm E2-containing silastic capsule and treated with
mifepristone. All points represent the mean + SEM of three determinations, except for E2 control (day 1)
and 1.0 mg mifepristone (day 21) which represent two determinations + range. All treatment groups given
the E2 capsule maintained a physiological level of E2 throughout the experiment
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TABLE 1. Histological Classification of the Cynomolgus Endometrium Developed Under Different Steroid Treatments.
Group
(ti=3)

Thickness
(mm ± SEM)

Glandular
morphology

Glandular mitotic
activity1

Stromal mitotic
activity2

Histological
classification

Vehicle

0.92 ±0.1*

small rounded

0/10

0/10

atrophic

E2 control

2.83 ± 0.3b

dilated tubular

19/10

0.3/10

mid proliferative

tubular

10/10

0,3/10

mid proliferative

small rounded

3/10

0/10

weak proliferative

small rounded

1.7/10

0/10

very weak

E2 plus mifepristone 2.11 ±0.2b
(0.01 mg/kg)
E2 plus mifepristone 1.6410.1*
(0.1 mg/kg)
E2 plus mifepristone 0.67 ±0.1*
(1.0 mg/kg)

proliferative

Animals were treated with either a 3 cm E2-containing silastic implant or a vehicle-containing implant for 2 1 days. Daily injections of mifepristone (at doses
indicated) began on day I and were continued for an additional 19 days. Uterine biopsies were obtained on day 21.
1Glandular mitotic activity = average number of mitotic cells/10 glands.
2Stromal mitotic activity = average number of mitotic cells/10 fields @ 400X,
Means with different superscripts are significantly different (P<0,0S),
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Antiestrogenic Effects o f Mifepristone on Monkey Endometrium

Histological results showing the effect of mifepristone on monkey endometrium
are illustrated in Table I and Figure 4. In the vehicle control group, the lack of ovarian
steroids was associated with endometrium showing very densely positioned nuclei in the
stroma and being completely void o f glandular and stromal mitotic activity (Fig. 4A). With
the addition of E2 to the experimental model (E2 control group), a marked induction of
endometrial growth was observed. The endometrial classification for this group of
monkeys was mid-proliferative, as shown by appearance of dilated tubular-shaped glands,
stromal edema, and presence of glandular mitotic activity (Fig. 4B). The mean endometrial
thickness in the E2 control group was significantly different from the vehicle control group
(P<0.01). In relationship to the E2 control group, treatment with E2 plus 0.01 mg/kg
mifepristone did not inhibit E2-induced endometrial growth (P>0.05) nor affect general
endometrium morphology (Fig. 4C). Increasing the dose of mifepristone to 0.1 mg/kg,
reduced the level of glandular mitotic activity, produced an endometrium with small
rounded glands, and further reduced the endometrial thickness (Fig. 4D). The endometrial
thickness of the 0.1 mg/kg mifepristone group was not different from either the vehicle
control or E2 control groups (P>0.05), indicating the appearance of antiestrogenic effects.
Animals treated with 1.0 mg/kg mifepristone showed a further reduction in glandular
mitotic activity and a compact stromal morphology closely resembling that in the vehicle
control group. As shown in Figure 4E the glands were few, small and rounded. The
endometrial thickness attained in the 1.0 mg/kg mifepristone group was not different from
the vehicle control group (P>0.05), and was different from the E2 control group
(P0.001). Histological classification o f the 1.0 mg/kg mifepristone group was weak
proliferative and not atrophic, as in the vehicle control group. This difference in
classification indicates that mifepristone can suppress growth of the endometrium to a
level equal to the vehicle control, yet at the same time does not completely inhibit all
estrogenic activity.
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F ig. 4. Comparison o f endometrial appearance from cynomolgus monkeys treated with E2 plus
mifepristone. Paraffin embedded tissue was sectioned at 5pm, stained with H&E and photographed at
(X40). Tissue from the vehicle control group (panel A) shows a dense, compact stromal cell density with
no observable edema. In contrast, tissue from the E2 control group (panel B) is characterized by increased
endometrial thickness, elongated dilated glands, and stromal edema. (*) Approximate border o f the
endometrium and myometrium.

R ep ro d u ced with p erm ission o f the copyright ow ner. Further reproduction prohibited w ithout p erm ission.

F ig .

4. (continued). Photographs of monkey endometrial tissue. Tissue from the E2 + 0.01

mg/kg mifepristone treatment group (panel C) shows tubular glandular morphology and stromal edema.
Endometrium thickness in this group did not differ from the E2 control group (P>0.05). Panel D shows
endometrial tissue from the E2 + 0.1 mg/kg mifepristone treatment group, tissue from this group was
characterized by small round glands, decreased stromal edema, and decreased endometrial thickness.
Endometrial thickness of this group did not differ from the vehicle control group or E2 control group
(P>0.05). (*) Approximate border of the endometrium and myometrium.
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Fig. 4. (continued). Photograph shows endometrial tissue from the E2 +

1.0 mg/kg mifepristone

treatment group (panel E). The endometrium in this group was marked by an almost complete lack of
glands stromal compaction, and an endometrial thickness not different from the vehicle control group
(P>0.05). (*) Approximate border o f the endometrium and myometrium.
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Rat Preliminary Experiments
A series of experiments using the rodent model were conducted to determine
optimal doses of E2 and mifepristone required to affect uterine imbibition and uterine
blotted weight. As our overall study design included establishment of a rodent model to
replace the primate uterine model, our initial studies used adult rats as a comparative
physiological model for adult monkeys.
Figure 5 illustrates the increase in uterine wet weight in response to various doses
of E2. The ideal E2 dose desired would be a value approximating the midpoint of the
uterine response curve. As shown in Figure 5, the E2 dose most closely meeting this
criteria was 6 |ig E2/100 g BW; consequently, this dose was then selected to be used in
subsequent experiments.

Estrogen dose response
3r

1■■
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20

ug E2/IOOg BW

Fig. 5. Estrogen dose response curve. Ovariectomized adult rats were treated once daily for 3 days with
various doses of E2 (in oil, sc). Uterine wet weight values were determined on the morning o f day 4.
Animals In this experiment were ovariectomized £4 days prior to steroid treatment
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TABLE 2. Preliminary Experiment 1. Uterine Weights of Ovariectomized Adult Rats1 Treated for 3 Days
with 6pg E2/100 g BW plus Mifepristone.

wet weight (g)

blotted weight (g)

Treatment

mean ± SEM

mean ± SEM

Vehicle control

0.307 ±0.015*

0.293 ±0.014*

E2 control

1.627 ± 0.13 lb

0.547 ±0.014b

E2 + 0.005 mg mifepristone

1.597 ±0.144b

0.565 ± 0.021b

E2 + 0.05 mg mifepristone

1.646 ±0.196 b

0.588 ±0,068 b

E2 + 0.5 mg mifepristone

1.206±0.138b

0.548 ±0,031b

'Rats were given a £4 day post-ovariectomy recovery period before starting steroid treatment.
Treatment means with a different superscript are significantly different (P<0.05),
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TABLE 3. Preliminary Experiment 2. Uterine Weights of Ovariectomized Adult Rats1 Treated for 3 Days
with 6|ig E2/100 g BW plus Mifepristone.

wet weight (g)

blotted weight (g)

Treatment

mean ± SEM

mean ± SEM

Vehicle control

0.216 ± 0.007*

0.211 ±0.007*

E2 control

1.340 ± 0.171b

0.497 ± 0.034 b

E2 + 0.5 mg mifepristone

1.535 ±0.184b

0.486 ± 0.028 b

E2 + 1,5 mg mifepristone

1.121 ±0.108b

0.460 ± 0.01 l b

E2 + 5.0 mg mifepristone

1.203 ±0.155b

0.459 ±0.015 b

'Rats were given a £10 day post-ovariectomy recovery period before starting steroid treatment.
Treatment means with a different superscript are significantly different (P<0,05).
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Previous studies already mentioned that used the monkey model had indicated that
mifepristone inhibited endometrial proliferation. In an effort to maintain a similar
mifepristone dose (mg/kg) in the rat model, we began these studies examining the effect of
0.005 mg, 0.05 mg, and 0.5 mg mifepristone, total dose per animal (doses approximate
0.015 mg/kg, 0.15 mg/kg, and 1.5 mg/kg). In addition, the rat uterine weight bioassay
conventionally uses a 3 day steroid treatment period and we followed this accepted
protocol.
Data from Preliminary Experiment 1 did not identify antiestrogenic effects of
mifepristone in adult rats, as determined by a decrease in uterine imbibition or uterine
blotted weight (P>0.05, Table 2). Consequently, in our following experiment we chose to
increase the mifepristone total dose per animal to 0.5 mg, 1.5 mg, and 5.0 mg. Data from
this experiment (Preliminary Experiment 2) show that even these high levels of
antiprogestin did not inhibit the increase in uterine wet and blotted weights induced by 6
Mg E2/100 g BW (P>0.05, Table 3). Concern was expressed that the dose o f 6 pg E2/100
g BW may establish serum E2 levels exceeding the physiologic range, and therefore,
possibly over-ride the noncompetitive antiestrogenic effects of mifepristone. The dose 0.5
Mg E2/100 g BW was selected from the literature (L’Horset et al., 1993) as sufficient to
mimic E2 peak levels during proestrus. Uterine weights of adult rats treated with 0.5 pg
E2/100 g BW and mifepristone are shown in Table 4 (Preliminary Experiment 3). These
data show that all treatment groups receiving mifepristone were not significantly different
from the E2 control group (P>0.05).
It had been reported that ovariectomized rats not pretreated with E2 failed to
respond to progestin treatment (Kraus and Katzenellenbogen, 1993; L’Horset et al.,
1993). The lack of response is thought to be due to decreased expression of PR. As our
previous three experiments failed to identify antiestrogenic effects of mifepristone in the
ovariectomized rat, it was possible that the lack of response was due to very low uterine
PR expression. To determine if E2 pretreatment was necessary in our rodent model, we
treated rats with 0.5 pg E2/100 g BW for 3 days, followed by the same dose of E2 plus
mifepristone for 3 consecutive days (Preliminary Experiment 4). Mifepristone did not
demonstrate any antiestrogenic affects under these conditions. Thus, results of this
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experiment show that E2 pretreatment did not affect the capacity of mifepristone to cause
antiestrogenic effects in adult rats (P>0.05, Table 5).
Kraus and Katzenellenbogen (1993) have reported antiestrogenic effects of
mifepristone in ovariectomized immature rats as determined by a decrease in uterine
imbibition. Since the methodology used by these authors differed considerably from our
own, we believed it necessary to conduct a comparative study. A Latin Square 2x2 study
was designed to test adult rats versus immature rats given E2 replacement as either 0.5 pg
E2/100 g BW or 0.5 mg E2 pellet.
Although the treatment regime modeled after that described by Kraus and
Katzenellenbogen (1993), i.e., Preliminary Experiment 4, did not identify noncompetitive
antiestrogenic effects of mifepristone, we empirically chose to continue this treatment
regime. The variable, post-ovariectomy recovery period, was held at 10 days for adult rats
to facilitate ovarian steroid clearance and uterine atrophy. To replicate the experiment
described by Kraus and Katzenellenbogen (1993), we were obligated to observe the 4 day
surgery recovery period for immature rats. In addition, we continued to use the E2 dose of
0.5 pg E2/100 g BW to maintain E2 stimulation within the physiologic range.
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TABLE 4. Preliminary Experiment 3. Uterine Weights of Ovariectomized Adult Rats1 Treated for 3 Days
with Physiologic Levels of E2 Replacement (0.5 pg E2/100 g BW) plus Mifepristone.

wet weight (g)

blotted weight (g)

Treatment

mean ± SEM

mean ± SEM

Vehicle control

0.204 ±0.018*

0.201 ±0.017*

E2 control

1.179 ± 0.073b

0.442 ± 0.039 b

E2 + 0.1 mg mifepristone

1.080 ±0.144b

0.445 ± 0.029 b

E2 + 0.5 mg mifepristone

1.203 ±0.170b

0.452 ± 0.032 b

E2 + 1.5 mg mifepristone

1.114±0.110b

0.466 ± 0.032 b

E2 + 5.0 mg mifepristone

1.192 ± 0.096 b

0.484 ± 0.032b

'Rats were given a £10 day post-ovariectomy recovery period before starting steroid treatment.
Treatment groups with a different superscript are significantly different (P<0.05).
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TABLE S. Preliminary Experiment 4. Effect of E2 Pretreatment on Uterine Weights of Ovariectomized
Adult Rats1 Treated for 3 Days with 0.5 pg E2/100 g BW plus Mifepristone.

wet weight (g)

blotted weight

Treatment

mean ± SEM

mean ± SEM

Vehicle control

0.195 ± 0,004'

0.192 ± 0.003'

E2 control

0.841 ±0.216'

0.518 ± 0.031b

E2 + 0.1 mg mifepristone

1.088 ±0.252'

0.531 ± 0.040b

E2 + 0.5 mg mifepristone

1.006 ±0,188'

0.484 ± 0.023b

E2 + 1.5 mg mifepristone

0.881 ±0.179*

0.493 ±0.012b

E2 + 5.0 mg mifepristone

1.168 ±0.109*

0.517 ±0.014b

Animals were pretreated with E2 at O.S pg E2/100 g BWalone for 3 days, followed by an additional 3 days of E2 plus mifepristone
or E2 alone. Treatment groups with a different superscript are significantly different (P<0.03).
'Rats were given a £10 day post-ovariectomy recoveiy period before starting steroid treatment.
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Rat Endocrine Analysis

In order to establish the approximate serum E2 levels attained by the two different
E2 delivery methods, we treated a representative group of animals and collected cardiac
blood samples on days 1 (pretreatment control), 3, 5, and 7. The mean serum E2 values
are shown in Figure 6. Administration of 0.5 pg E2/100 g BW to both immature and adult
rats maintained daily average serum E2 levels in the range of 10-35 pg/ml. These values
correspond to physiologic levels attained in diestrus and proestrus. In comparison, animals
given the 0.5 mg E2 pellet attained extraordinary supraphysiologic serum levels of E2.
These values ranged from 80- to 600-fold greater than the levels reached by treatment
with 0.5 pg E2/100 g BW. The higher E2 levels measured in the immature rats versus
adult rats are possibly due to the difference in volume of distribution and/or slower hepatic
metabolism.

Rat estradiol levels
10000
'Adult, 0.5 mg
1000
'Adult, 0.5 ug/lOOg BW

4a.

100

'Immature, 0.5 mg
-Immature, 0.5 ug/lOOg
BW

1

3

5

7

Days of treatment

Fig. 6. Seram estradiol levels in adult and immature rats. Animals were either implanted on day 1with a
0.5 mg E2 pellet, sc, or treated daily with 0.5 tig E2/100 g BW for 6 days. Serum samples were collected
by cardiac puncture on the days indicated. Animals receiving the 0.5 mg pellet attained E2 levels 80- to
600-fold greater than animals given 0.5 \ig E2/100 g BW. All points represent the mean + SEM of three
determinations, except immature day 1 (control) which represents mean + range of two determinations.
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Antiestrogenic Effects o f Mifepristone on the Estradiol-Primed Rat Uterus

In contrast to the monkey data, the rat uteri did not manifest the capacity of
mifepristone to curtail endometrial growth, even at doses 16-fold greater (mg/kg) than
that used in the monkey. Interestingly, mifepristone did appear to impair water retention in
certain experiments, even while the rat uterine weight bioassay proved inappropriate for
the demonstration of the antiproliferative actions o f this antiprogestin.

F ig . 7. Effect of 0.5 (ig E2/100 g body weight on adult rat uterine tissue. (A) Control tissue, (B) E2
treated tissue. Note uterine ballooning and increased tissue growth induced by the treatment with
estrogen.
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In the first experiment, the antiestrogenic effect of mifepristone was assessed in
adult animals treated with 0.5 pg E2/100 g BW/day. The uteri of animals from the vehicle
control group were small, flaccid, and contained a negligible weight of fluid (Fig. 7A). In
contrast, the uteri of animals from the E2 control group were large and turgid (Fig. 7B).
The E2 control group had a mean fluid volume of 0.3 ml and showed a 3.6-fold increase in
wet weight and a ~2-fold increase in blotted weight compared to that observed in the
vehicle control group. These results clearly illustrate that this amount of E2 does have
stimulatoty effects on rat uterine tissue.
The uterine wet and blotted weights of adult rats treated with 0.5 pg E2/100 g BW
are shown in Figure 8. In this experiment, uterine weights of all treatment groups
receiving mifepristone did not differ from their respective E2 control (P>0.05; Fig. 8A and
B).
Similar results were obtained in the second experiment which assessed the
antiestrogenic effects of mifepristone in immature animals treated with 0.5 pg E2/100 g
BW/day. In this experiment, uteri of animals from the E2 control group showed a 4-fold
increase in both uterine wet weight (P<0.05; Fig. 9A) and blotted weight (P<0.05; Fig.
9B) in comparison to the vehicle control group. As in the adult rat experiment, the
immature rat uterine wet and blotted weights from all mifepristone-treated groups did not
differ from their respective E2 control group (P>0.05). Taken together, data from these
two experiments indicate that mifepristone does not affect the change in uterine wet
weight or uterine blotted weight induced by 0.5 pg E2/100 g BW.
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Adult rats given 0.5 ug E2/100 g BW
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Fig. 8. Uterine weight values attained in adult rats given 0.5 pg E2/100 g BW/day and treated with
mifepristone. Treatment groups are: vehicle control (V); estradiol control (E2); E2 + 0.1 mg mifepristone;
E2 + 0.5 mg mifepristone; E2 +■ 1.5 mg mifepristone; and E2 + 5.0 mg mifepristone. Each column
represents the mean + SEM for five determinations. Columns with a different superscript are significantly
different (P<0.05). Uterine wet and blotted weights in the mifepristone treated groups were not
significantly different from their respective E2 control group. Columns without bars indicate that the SEM
is within the column.
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Immature rats given 0.5 ug E2/I00 g BW
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Fig. 9. Uterine weight values attained in immature rats given 0.5 pg E2/I00 g BW/day and treated with
mifepristone. Treatment groups are: vehicle control (V); estradiol control (E2); E2 + 0.1 mg mifepristone;
E2 + 0.5 mg mifepristone; E2 + 1.5 mg mifepristone; and E2 + 5.0 mg mifepristone. Each column
represents the mean + SEM for five determinations. Columns with a different superscript are significantly
different (P<0.05). Animals treated with mifepristone did not show a decrease in uterine wet or blotted
weights in comparison to their respective E2 control group. Columns without bars indicate that the SEM
is within the column.
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Previous work by Kraus and Katzenellenbogen (1993) reported antiestrogenic
effects of 1.5 mg mifepristone in immature rats treated with a 0.5 mg E2 pellet. As our
previous experiments failed to detect any antiestrogenic effect of mifepristone in rats
treated with 0.5 pg E2/100 g BW, we were interested in comparing our experimental
model to that of Kraus and Katzenellenbogen.
In this experiment adult animals treated with a 0.5 mg E2 pellet showed a
tremendous increase in uterine wet weight (2.21 g) in comparison to the vehicle control
(0.2 g). This increase in uterine wet weight was inhibited by treatment with mifepristone at
all doses (P<0.05; Fig. 10A), with there being no statistically significant difference
between the lowest and highest dose groups. The uterine blotted weight of the 0.1 mg
mifepristone and 0.5 mg mifepristone groups were different from the E2 control group
(P<0.05; Fig. 10B), however, this significance was marginal since the alpha probability
was between 0.04 and 0.05. Blotted uterine weights of the 1.5 mg and 5.0 mg
mifepristone groups were not significantly different from the E2 control (P>0.05).
When immature animals were treated with the 0.5 mg E2 pellet, an ~ 15-fold
increase in uterine wet weight and 5-fold increase in uterine blotted weight were observed
in comparison to the vehicle control, (0.62 g vs 0.04 g) and (0.2 g vs 0.04 g) respectively.
Similar to that shown in the adult animals, all doses of mifepristone were able to inhibit the
E2-induced increase in uterine wet weight (P<0.01; Fig. 11A). In addition, mifepristone
decreased uterine blotted weight by approximately 15% in all treatment groups (P<0.05;
Fig. 1IB). These data are in agreement with Kraus and Katzenellenbogen (1993), who
reported a 17% decrease in uterine wet weight of animals treated with 0.5 mg E2 pellet
and 1.5 mg mifepristone.
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Adult rats given 0.5 mg E2 pellet
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Fig. 10. Uterine weights attained in adult rats given a 0.5 mg E2 pellet and treated with mifepristone.
Treatment groups are: vehicle control (V); estradiol control (E2); E2 + 0.1 mg mifepristone; E2 + 0.5 mg
mifepristone; E2 + 1.5 mg mifepristone; and E2 + 5.0 mg mifepristone. Each column represents the mean
+ SEM for five determinations. Columns with a different superscript are significantly different (P<0.05).
E2 control animals showed a dramatic increase in uterine wet weight This increase was effectively
inhibited by treatment with mifepristone at all four doses. Columns without bars indicate that the SEM is
within the column. *Note change in scale.
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Immature rats given 0.5 mg E2 pellet
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F ig . 11. Uterine weight attained in immature rats given a 0.5 mg E2 pellet and treated with
mifepristone. Treatment groups are: vehicle control (V); estradiol control (E2); E2 + 0.1 mg mifepristone:
E2 + 0.5 mg mifepristone; E2 + 1.5 mg mifepristone; and E2 + 5.0 mg mifepristone. Each column
represents the mean + SEM for five determinations. Columns with a different superscript are significantly
different (P<0.05). The E2 treated group showed a 15-fold increase in uterine weight in comparison to the
vehicle control group. This estrogen-induced weight increase was inhibited by treatment with
mifepristone. Columns without bars indicate that the SEM is within the column.
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Histological Analysis
To help understand the effect of mifepristone on rat endometrial morphology, uteri
from the four rat experiments were stained with H&E and histologically examined for
number of mitotic figures and cells with nuclear fragmentation. A comparison of these
parameters are shown in Tables 6 and 7. These data show that within each experiment, the
number of mitotic cells and cells with a fragmented nucleus in the E2 control group were
not significantly different from the mifepristone-treated groups (PX).05). As such, the
difference in uterine blotted weight observed in those experiments using the 0.5 mg E2
pellet is not due to a mifepristone-induced decrease in mitotic activity or increase in cell
death. It is interesting to note that in animals given 0.5 jig E2/100 g BW/day, the number
of mitotic cells and cells showing nuclear fragmentation were greater in relationship to
their age-matched counter parts given a 0.5 mg E2 pellet.
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TABLE 6. Number of Mitotic Figures1 (Mean ± SEM) Measured in Ovx, Adult and Immature Rats, Treated with
17P-Estradiol and Mifepristone.

Experimental

Vehicle

Estradiol

E2 + 0.1 mg

E2 + 0.5 mg

E2 + 1.5 mg

E2 + 5.0 mg

model

control

control (E2)

mifepristone

mifepristone

mifepristone

mifepristone

Adult rats

2± 1

44 ±8

38 ±4

34 ±7

36 ±4

36 ± 5

2 ±0.5

6± 1

9 ± 1,5

8± 1

9± 1

7± 1

0.2 ± 1

18 ± 5

15 ±4

14 ±2

17 ± 3

26 ±5

0± 0

3 ±0.5

4 ±0.5

3 ±0.4

3 ±0.5

4± 1

0.5 pgE2/100g
Adult rats
0.5 mg E2 pellet
Immature rats
0,5 pgE2/100g
Immature rats
0.5 mg E2 pellet

Animals were pretrcated with E2 at (0,5 pg/lOOg BW) or (0.5 mg pellet) alone for 3 days, followed by an additional 3 days of E2 plus mifepristone or E2
alone. Mifepristone treated groups were not significantly different from their respective E2 control group (P> 0,05).
1Mean number of cells/tissue cross-section/animal.
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TABLE 7. Number of Cells with Nuclear Fragmentation1 (Mean ± SEM) Measured in Ovx, Adult and Immature Rats,
Treated with 17p-Estradiol and Mifepristone.

Experimental

Vehicle

Estradiol

E2 + 0,1 mg

E2 + 0.5 mg

E2+ 1.5 mg

E2 + 5.0 mg

model

control

control (E2)

mifepristone

mifepristone

mifepristone

mifepristone

Adult rats

0.1 ±0.1

13 ±9

21 ±15

31 ±21

27 ±8

45 ±35

0.2 ±0.2

1 ±0.5

3± 1

2± 1

1,5 ± 0.5

1.5 ±0.5

0± 0

10 ± 3

8 ±4

4± 1

10 ± 3

11 ±3

0 ±0

0.5 ±0.4

0.5 ±0.3

0.4 ±0.2

0.5 ±0.3

0±0

0.5 pgE2/100g
Adult rats
0.5 mg E2 pellet
Immature rats
0,5 pg E2/100 g
Immature rats
0.5 mg E2 pellet
Animals were pretreated with E2 at (0.5 pg/100 g BW) or (0.5 mg pellet) alone for 3 days, followed by an additional 3 days of E2 plus mifepristone or E2
alone. Mifepristone treated groups were not significantly different from their respective E2 control group (P> 0.05).
1Mean number of cells/tissue cross-section/animal.
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DISCUSSION

Before our laboratory’s initial reports in 1989, there was no appreciation of a class
of antiprogestin compounds that conferred antiestrogenic/antiproliferative effects upon
uterine tissue. Accordingly, in the absence of binding to the ER, antiestrogenic effects of
mifepristone were simply not anticipated. Although the primate is an extremely useful
animal model for comparative physiological studies in humans, considerable financial and
ethical issues remain a constant companion when conducting primate research. As such,
the application of other animal models to replace the primate is important.
The immature rat uterus is frequently used by corporate scientists as a target organ
for high-throughput screening of estrogenic compounds. Two easily observable classic
responses in the rat uterus to exogenous estrogen include increased cell proliferation and
water retention. Utilization of the rat model greatly decreases the economical and ethical
burdens surrounding the use of primates in research. Therefore, it is prudent for
investigators to use this less controversial animal model when possible.
The experiments reported herein, have examined the ability of the rat uterine
weight assay to detect previously established noncompetitive antiestrogenic effects of
mifepristone on estrogen-induced endometrial proliferation. Our findings suggest that the
rat uterine weight bioassay is not an appropriate laboratory model suitable for screening
antiprogestins for medical indications in which women’s tissues grow in response to
estrogen.
Results from our nonhuman primate experiment have clearly confirmed the
noncompetitive antiestrogenic effect of mifepristone on endometrial proliferation. These
data by themselves although not novel, do confirm the antiestrogenic nature of
mifepristone and allow a direct comparison to the rat model. The present experiment and
those of others (van Uem et al., 1989; Wolf et al., 1989b; Neulen et al., 1990; Slayden and
Brenner, 1994) all show that mifepristone reliably inhibits E2-induced endometrial
proliferation in ovariectomized monkeys in a dose dependent manner. Stromal compaction
was not statistically evident in this study at the two lowest mifepristone doses (0.01 and
0.1 mg/kg). However, the 0.1 mg/kg dose appeared to be a partially effective dose as the
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endometrial thickness did not differ from either the vehicle control or E2 control groups.
The 1.0 mg/kg mifepristone dose did not induce development of an atrophic endometrium
as shown in the vehicle control group. This limited ability of mifepristone to completely
suppress estrogenic effects may increase its applicability to treat various diseases.
During this experiment, all monkeys were observed daily for the presence of
menstrual bleeding. Throughout the entire 21 day study period, all animals remained
amenorrheic (data not shown).
Our preliminary rat experiments that used adult animals and various treatment
regimes did not identify noncompetitive antiestrogenic effects of mifepristone. As our
nonhuman primate data clearly shows the noncompetitive antiestrogenic capacity of
mifepristone, validity of the rat uterine weight assay was brought into question. To correct
for the possible lack of, or paucity of progesterone receptor and ineffectiveness of
mifepristone in the rat model, the total treatment time was lengthened to 6 days; 3 days of
E2 pretreatment, and 3 days of E2 plus mifepristone treatment. Indeed, E2 pretreatment
may be necessary to upregulate the progesterone receptor in ovariectomized rats before
effects of progestins can be assessed (Katzenellenbogen, 1980; L’Horset et al., 1993).
The mean serum E2 levels in rats given 0.5 pg E2/100 g BW were in the normal
physiologic range of diestrus and proestrus. In comparison, serum E2 levels established in
rats given the 0.5 mg E2 pellet were pharmacologic. Animals treated with the E2 pellet
maintained a daily mean serum E2 level ranging from 80- to over 600-fold greater than
rats given 0.5 pg E2/100 g BW. These values are much higher than the 40 pg/ml average
for the proestrus estradiol surge in rats (Smith et al., 1975). The lower level of serum E2
established by 0.5 pg E2/100 g BW did not stimulate as dramatic an increase in uterine
wet weight in the E2 control animals as did treatment with the 0.5 mg E2 pellet. In
addition, rats given 0.5 pg E2/100 g BW did not show a decrease in uterine wet weight
when treated with mifepristone. At this time the association between serum E2 levels and
the capability of mifepristone to affect uterine wet weight is not felly understood.
It has been reported by Kraus and Katzenellenbogen (1993) that ovariectomized
immature rats treated with a 0.5 mg E2 pellet show a down-regulation in uterine ER
expression. After 2 days of treatment, uterine tissue from rats receiving the E2 pellet
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expressed only 15% of control ER levels, and this level remained steady throughout the
remaining 6 day treatment period. Levels of uterine PR (B isoform) were also measured in
these same animals. A 7-fold increase in PR levels was attained after 2 days of treatment
and a 10-fold increase was attained by end of the 6 day treatment period. The regulation
of steroid receptors in ovariectomized rats given various levels of E2-supplementation has
also been reported by Manni and others (1981). These authors report that rats given from
0 to 50 pg E2/day for 5 days show a dose-related decrease in total level of uterine
estrogen receptors. Although uterine ER and PR expression were not measured in our
experiments, it is likely our animals given the 0.5 mg E2 pellet would have shown a similar
regulation of these steroid receptors. The possible increased number of ERs in our animals
given 0.5 pg E2/100 g BW is supported by the observation of a greater number of mitotic
cells in these animals; which is a classic estrogen-driven response. The increased mitotic
index in these animals occurred despite having much lower serum E2 levels in comparison
to animals given the 0.5 mg E2 pellet. These data would then suggest that the decreased
numbers of mitotic cells observed in the E2 pellet-treated animals could be due to downregulation of the ER. If these assumptions are valid, it appears that the decrease in uterine
wet weight caused by mifepristone in our experiments required the presence of a low level
of ER expression, a high level o f PR expression, and a high serum E2 level. Slayden and
Brenner (1994) have proposed that increased levels of PR expression is important for the
ability of mifepristone to have antiestrogenic effects in the rhesus monkey. Up-regulation
of the PR may provide a mechanism by which squelching or quenching of estrogen gene
activity could occur. Therefore, it is possible that the ratio ofPR.ER coupled with high
serum E2 levels are key factors that may regulate the ability of mifepristone to have
antiestrogenic effects in the rat.
Mifepristone decreased the uterine blotted weight of rats in both experiments that
used the 0.5 mg E2 pellet. Although statistically significant, the absolute weight
differences between treatment groups within these two experiments is very small, and as
such, emphasis should not be strongly placed upon the difference. When comparing agematched rat experiments, it is evident that E2 replacement given as 0.5 pg /100 g BW
versus 0.5 mg pellet, led to approximate equal uterine blotted weight values; yet at the
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same time, those animals treated with 0.5 pg E2/100 g BW had greatly increased numbers
of mitotic cells and cells showing nuclear fragmentation. The disparity of these data
indicate that the observed decrease in uterine wet weight in animals given a E2 pellet was
more likely due to a decrease in uterine fluid retention, and not in addition, the apparent
inhibition of cell growth. Kraus and Katzenellenbogen (1993) also observed a decrease in
uterine wet weight in mifepristone treated rats. These authors interpreted their results as
an indication of the ability of mifepristone to inhibit E2-induced increase in uterine growth;
however, this assessment was made in the absence of histological evaluation. Although
our data do indicate a difference in mitotic and fragmenting cell numbers between
experiments, this activity was not associated with a change in uterine weight.
It has been proposed that mifepristone elicits its antiestrogenic effects via the PR A
isoform (McDonnell and Goldman, 1994). The absence of observed antiestrogenic effects
by mifepristone in these experiments is not due to the lack of PRA in the rat uterus, as
Ilenchuk and Walters (1987) have measured a 3:1 ratio of PRAiPRB in rat uteri. Second,
the only species identified to date that do not recognize mifepristone are the chicken,
hamster, and tammar wallaby (Benhamou et al., 1992; Lim-Tio et al., 1996). Lastly, it has
been reported that mifepristone does have antiprogestin effects in the rat, as shown by
impairment of implantation and embryo development (Psychoyos and Prapas, 1987;
Roblero and Croxatto, 1991), and pregnancy termination (Chang et al., 1993).
Other mechanisms have been proposed to describe the antiestrogenic effects of
mifepristone. Two of these mechanisms include, inhibition via PRA and PRB (Kraus et al.,
1995), or by an over expression of the ER (Neulen et al., 1996). It is apparent that the
observed inhibition is not due to a down-regulation of uterine ER, as both Slayden and
Brenner (1994) and Neulen and others (1996) have measured an increased expression of
ER in mifepristone treated animals. The mechanism(s) by which mifepristone induces its
antiproliferative effects on the nonhuman primate endometrium remains unknown.
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CONCLUSIONS
In the absence of both physiological and pharmacological serum estradiol levels,
failure of the rat uterine weight assay to confirm the nonhuman primate data indicating
curtailment of endometrial proliferation, illustrates an extreme limitation and brings in to
question the utility of using the rat uterine weight bioassay to screen lead antiprogestins
compounds for potential noncompetitive antiestrogenic activity. Although we only
analyzed the single antiprogestin mifepristone, it seems likely that other antiprogestins
possess antiproliferative effects on primate endometrium. Our data indicate that the
antimitogenic capability of these compounds would likely not be identified using the rat
uterine weight bioassay. In summary, the rat uterine weight bioassay, in contrast to the
primate uterine assay, is not a valid in vivo model for detecting, or for quantifying the
noncompetitive antiestrogenic/antiproliferative effects of mifepristone.
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